PHT Announces Partnership with ePharmaLearning to Improve Site Satisfaction
Market-leading eDiary provider first to market with cost-effective training solution
CHARLESTOWN, Mass. and PHILADELPHIA, Penn. - June 23, 2005 -- PHT Corporation, the leading provider of electronic patient reported outcome (ePRO) solutions used in over 160 trials worldwide, and ePharmaLearning, the leading provider of eCollaboration tools for clinical development, are partnering to offer advanced eTraining solutions to improve site satisfaction.Through the agreement, ePharmaLearning is collaborating with PHT to deliver a cost-effective online training offering for sites on PHT's eSource applications including LogPad, StudyPad" and StudyWorks".
The eLearning modules, which address topics ranging from setting up a LogPad to running subject compliance reports in StudyWorks, are fully animated and narrated. They are always available on-demand throughout the study to supplement the training sessions delivered at the initial Investigator Meeting. The interactive online modules include simulation exercises, a training certification test and complete training records for each user that completes the online tutorial.
"Our experience shows that effective training is an essential component of a successful ePRO solution," said Phil Lee, PHT President and CEO. "Our partnership with ePharmaLearning adds value to customers through supplemental eLearning solutions which are scaleable, cost effective and easy to use."
ePharmaLearning's customized training educates site personnel on the details of the LogPad or StudyPad system and improves the site coordinators' ability to help subjects unfamiliar with eDiaries enabling sponsors to better leverage their investment in ePRO. ePharmaLearning CEO Lance Converse states that clients also benefit from the added efficiency of online training, which is typically 80% less than the cost of traditional in-person training. In addition, it can be delivered in one-third of the time, with equivalent learning outcomes.
"PHT and ePharmaLearning share a number of top pharmaceutical clients, which makes the partnership a natural fit," said Converse. "By delivering high quality, scalable training, we are able to help leading biopharmaceutical companies improve efficiencies and site satisfaction. This can in turn, reduce trial timelines and increase subject compliance. We are excited to be working with PHT as the first ePRO solution provider to provide advanced online training services to their clients."
Lee and Converse agree that the already high customer demand for electronic training methods will only increase over time, citing the growing trend of hosting Investigator Meetings online as an example.
About ePharmaLearning
ePharmaLearning, Inc. (www.epharmalearning.com) is a leading provider of clinical services that improves the way sites are selected, trained and activated to commence clinical trials. By incorporating more effective site recruitment and enrollment feasibility processes with adult-learning enriched protocol and procedure training, ePharmaLearning has helped improve sitequality and performance to over 40,000 clinical researchers in 50 countries for 18 of the top 20 pharmaceutical companies in the world. ePharmaLearning is headquartered in Philadelphia with offices in London. For more information call 610-832-9915.
About PHT Corporation
PHT Corporation is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in over 160 trials worldwide. Approximately 60 biopharmaceutical and medical device companies, including 13 of the top 15 drug development firms in the world, rely on PHT's innovative and comprehensive ePRO solutions for their Phase I-IV clinical studies. PHT's integrated Product Suite enables successful clinical trials by improving data quality, reducing data variance, and providing real-time access and analysis of the data collected. PHT has experience with more than 70,000 subjects at 8,000 clinical sites in 48 countries and 46 languages around the globe. PHT, a pioneer in developing innovative technology to meet clinical research's evolving needs, is headquartered in Charlestown, MA, and Geneva, Switzerland. For more information, please visit www.phtcorp.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
